2.920EUR+0.34%Mkt Cap: 603.16M $P/E: —Today
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese ence…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap603.16M $
Enterprise Value699.58M $
Revenue (TTM)155.37M $
Gross Profit73.39M $
Net Income (TTM)-125.21M $
Revenue/Share0.8707 USD
Last Price2.920 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees620
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0004056851
Valuation
P/E (Trailing)—
P/E (Forward)19.00
PEG-13.06
EV/EBITDA-6.52
EV/Revenue4.50
P/S3.88
P/B6.80
EPS (TTM)-0.90
EPS (Forward)0.15
52W Range
2.03327% of range5.335
52W High5.335 EUR
52W Low2.033 EUR
Profitability
Gross Margin38.66%
Oper. Margin-74.92%
EBITDA Margin-69.07%
Profit Margin-65.95%
ROE-108.50%
ROA-28.88%
Growth
Revenue Growth-27.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-57.49M $
CapEx (TTM)4.87M $
FCF Margin-29.73%
FCF Yield-7.66%
Net Debt96.42M $
Net Debt/EBITDA-0.90
Balance Sheet
Debt/Equity1.95
Current Ratio2.16
Quick Ratio1.33
Book Value/Sh0.4300 EUR
Cash/Share0.6410 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.193 EUR
Upside (mean)+112.1%
Target Range2.150 EUR – 12.00 EUR
€2.150+112.1% to mean€12.00
# Analysts7
Ownership
Shares Out.189.65M
Float157.26M
Insiders10.72%
Institutions24.42%
Technical
SMA 502.304 (+26.8%)
SMA 2003.224 (-9.4%)
Beta1.35
S&P 52W Chg18.16%
Avg Vol (30d)886.62K
Avg Vol (10d)1.93M
Technical Indicators
RSI (14)74.1
MACD0.1837
MACD Signal0.1080
MACD Hist.+0.0757
BB Upper3.094 EUR
BB Middle2.434 EUR
BB Lower1.775 EUR
BB Width54.18%
ATR (14)0.1713 EUR
Vol Ratio (20d)1.95x